MétaCan
Menu
Back to cohort
Record W2066072385 · doi:10.1016/s0895-7061(02)02890-x

Effects of inflammation on a model of cytochrome P450 dependent versus independent antihypertensives: losartan versus valsartan

2002· article· en· W2066072385 on OpenAlexaff
R LEWANCZUK

Bibliographic record

VenueAmerican Journal of Hypertension · 2002
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEicosanoids and Hypertension Pharmacology
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsMedicineLosartanPharmacokineticsValsartanCmaxPharmacodynamicsPharmacologyRheumatoid arthritisInternal medicineDosingPlaceboAngiotensin IIBlood pressurePathology

Abstract

fetched live from OpenAlex

Previous studies have demonstrated that the pharmacokinetics of cytochrome P450 (CYP450) metabolized drugs may be altered in inflammation. The objective of this study was to determine whether the pharmacokinetics and associated pharmacodynamics of a CYP450-activated drug (losartan) would be affected by inflammation when compared to a non-CYP450 metabolized drug (valsartan). Fourteen patients with acute rheumatoid arthritis, 12 patients with rheumatoid arthritis in remission and 8 healthy controls took part in this study. Losartan 100 mg or valsartan 160 mg were administered as a single oral dose in a double-blind, randomized order to study subjects. At specified intervals after dosing, blood was sampled for measurement of valsartan, losartan and losartan active metabolite, EXP3174, levels. Pharmacodynamic measurements were carried out at the same time as pharmacokinetic measurements using an HDI Pulsewave monitor. Results were assessed based on clinical categorization as well as continuously based on inflammatory mediator levels. When assessed by clinical status, conversion of losartan to EXP3174 was inhibited in the acute and remittive rheumatoid arthritic patients compared to healthy controls (p=.024 for AUC EXP3174 and p=.037 for Cmax EXP3174, by ANOVA). Pharmacokinetics of valsartan were not significantly different between clinical groups (p=.92 by ANOVA). When assessed continuously based on baseline C-reactive protein level (CRP), the AUC ratio for EXP3174:losartan was inversely related to CRP(r=-.49, p=.004). Similar correlations were seen when tender swollen joints or total serum nitrites were used as dependent variables. In terms of pharmacodynamics, the Cmax of EXP3174 and the Cmax ratio of EXP3174:losartan correlated with maximum changes in mean arterial pressure and with area under the effect curves for mean arterial pressure and a number of other clinical variables. In multiple regression models, Cmax of EXP3174 was the strongest predictor of clinical effect for losartan. No pharmacodynamic differences were seen for valsartan when analyzed categorically by clinical status or continuously by various inflammatory markers. We conclude that in the presence of inflammation the activation or metabolism of CYP450-dependent angiotensin II receptor blockers such as losartan may be altered leading to changes in pharmacokinetics and hence, clinical effect. Non-CYP450 dependent ARBs such as valsartan seem to be unaffected by inflammation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.256
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2002
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Journal of HypertensionSame topicEicosanoids and Hypertension PharmacologyFrench-language works237,207